E. coli-derived rhBMP-2 offers similar fusion success to AIBG in posterolateral lumbar fusion
Efficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in posterolateral lumbar fusion: an open, active-controlled, randomized, multicenter trialSpine J. 2017 Dec;17(12):1866-1874
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
100 patients scheduled for posterolateral fusion due to severe spinal stenosis, grade 1 spondylolisthesis, or spondylolysis were randomized to graft material of either Escherichia coli-derived recombinant human bone morphogenetic protein-2 (rhBMP-2) in a hydroxyapatite carrier or an autologous iliac crest bone graft. Patients were assessed primarily for fusion success on CT at 12 and 24 weeks. Sec...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE